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AIM This study determined the prevalence of cholelithiasis and/or cholecystectomy in Rett 
syndrome, described gallbladder function in a clinical cohort, and identified 
recommendations for assessment and management of gallbladder disease. 
METHOD The incidence rate of cholelithiasis/cholecystectomy was estimated from data 
describing 270 and 681 individuals with a pathogenic MECP2 mutation in the Australian Rett 
Syndrome Database and the International Rett Syndrome Phenotype Database respectively. 
Gallbladder function in 25 females (age 3y 5mo-47y 10mo) with Rett syndrome was 
evaluated with clinical assessment and ultrasound of the gallbladder. The Delphi technique 
was used to develop assessment and treatment recommendations. 
RESULTS The incidence rate for cholelithiasis and/or cholecystectomy was 2.3 (95% CI 1.1 
to 4.2) and 1.8 (95% CI 1.0 to 3.0) per 1000 person-years in the Australian and International 
Databases respectively. The mean contractility index of the gallbladder for the clinical 
sample was 46.5% [SD 38.3%], smaller than for healthy individuals but similar to children 
with Down syndrome, despite no clinical symptoms. After excluding gastroesophageal reflux 
gallbladder disease should be considered as a cause of abdominal pain in Rett syndrome and 
cholecystectomy recommended if symptomatic. 
INTERPRETATION Gallbladder disease is relatively common in Rett syndrome and 
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What this paper adds 
 Gallbladder disease occurs more frequently in those with Rett syndrome compared 
with the general population. 
 Smaller gallbladder volumes and decreased contractility were found in Rett syndrome 
compared with healthy controls similar to those with Down syndrome.  
 Gallbladder disease should be considered in the differential diagnosis of abdominal 
pain when it presents in this disorder. 
 
Introduction  
Rett syndrome (RTT) is a severe neurodevelopmental disorder caused by mutations in the X-
linked methyl-CpG-binding-protein-2 (MECP2) gene.
1
 After a period of apparently normal 




and/or language skills, and the development of distinctive hand stereotypies and impaired 
gait. There are also supportive criteria including poor growth, respiratory irregularities, and 
the development of scoliosis.
2
 Many factors contribute to poor growth in RTT including 
altered oropharyngeal dysfunction and reduced food intake,
3,4
 and problems with 
gastroesophageal motility such as reflux and constipation.
5
 Dysmotility may result from 
absent primary or secondary intestinal waves and the presence of tertiary intestinal waves as 
observed during videofluoroscopy, with concurrent delayed gastric emptying and atony.
3
 In a 
recent questionnaire-based survey in the USA (n=983), feeding problems were reported in 
81% and gastrointestinal problems in 92% of individuals.
6
 Gastrointestinal dysfunction in 




In general, gallstones are rare in childhood and adolescence, with estimated 
prevalence between 0 and 2% in the small number of studies undertaken.
7-12
 However, there 
appears to be a higher prevalence in particular populations of children, such as those with 
Down syndrome with reported prevalences up to 25%.
13,14
 Clinical studies in Down 
syndrome indicate that the gallbladder is small with poor emptying after a meal, suggestive of 
hypomotility.
15
 Table I summarises the limited available literature relating to the prevalence 
of gallbladder disease in the general paediatric population and those with Down syndrome. In 
the US family survey, gallbladder disease was reported by parents of 3% of females with 
RTT
6
 and has also been noted in single case reports of a male
16
 and a female
17
 with RTT. 
Similar to Down syndrome, hypomotility of the gastrointestinal system in RTT could result 
in more frequent occurrence of gallbladder disease in comparison with the general paediatric 
population. However, the population-based prevalence of gallbladder disease in RTT remains 
unknown. 
 Gallbladder disease can be a significant medical problem associated with severe 
abdominal pain but gallstones can remain asymptomatic. Moreover, 17% of children with 
gallstones detected with ultrasonography were symptom-free and 24% presented with non-
specific abdominal pain.
8
 Given the severe degree of intellectual impairment associated with 
RTT and the frequent difficulties carers and clinicians often have in identifying the cause of 
pain and other symptoms,
18
 it is important to further investigate the prevalence of gallbladder 
disease in this population. It is also important to provide clinicians with recommendations to 
assist them in the timely management of this often forgotten gastrointestinal disorder. 
There are three parts to this study. Firstly, we investigated the occurrence of 




secondly, we assessed gallbladder function in a clinic sample of females with RTT; and, 
thirdly, we report clinical recommendations for the assessment and management of 
gallbladder disease in RTT developed using consensus methods.  
 
METHOD 
Part 1: Occurrence of gallbladder disease 
Data were sourced from two databases: the Australian Rett Syndrome Database (ARSD)
19
 
and the International Rett Syndrome Phenotype Database (InterRett).
20
 Initially established in 
1993, the ARSD is an ongoing systematically ascertained, longitudinal population-based 
register of all Australian Rett syndrome cases born since 1976.
19
 For this study eligible cases 
were those who fulfilled the revised diagnostic criteria for RTT,
2
 had a pathogenic MECP2 
mutation, and whose caregivers had returned a questionnaire on registration and one or more 
biennial follow-up questionnaires. Age at questionnaire return, mutation type, and most 
recent height and weight were extracted from the database along with data to describe 
whether the individual had developed cholelithiasis, cholecystitis, or biliary dyskinesia, and 
when diagnosis was made. Contact was made with caregivers of cases with a gallbladder 
disorder to confirm or refine the diagnosis. 
InterRett was established in 2003
20
 and is a phenotype database that contains 
information on RTT cases from multiple countries around the world. This analysis was 
restricted to individuals with a confirmed pathogenic mutation whose caregivers had 
completed a questionnaire. Specifically, families were asked if their child was diagnosed with 
any gallbladder or biliary disease. Age and mutation details were extracted from the database. 
A binary variable was created to indicate the occurrence or otherwise of a diagnosis of 
gallbladder disease. To facilitate calculation of the incidence rate of gallbladder disease, the 
observation time or years of follow-up was determined for each individual.For those who had 
had gallbladder disease, the observation time was the age at diagnosis and, for the remainder, 
the age at return of last family questionnaire or age at death. 
 
Statistical analyses 
Incidence rates of gallbladder disease for the ARSD and InterRett cohorts were estimated by 
dividing the number of newly diagnosed cases by the sum of observation times for each 
individual at risk. Confidence intervals (CI) for incidence rates were calculated using the 





Part 2: Gallbladder function in a clinic sample 
This component of the study was performed at the Department of Paediatrics and Adolescent 
Medicine of the Medical University Vienna. Patients were recruited through an advertisement 
in the local newsletter of the Austrian Rett Syndrome Society. The families of 25 females 
with classical RTT responded and provided written consent for study participation. Data 
collection included feeding history and assessment of growth using stadiometry. Fasting 
blood samples were taken for evaluation of blood cell count, lipids, hepatic function, and 
clotting tests. 
All individuals underwent abdominal ultrasonography in order to assess their 
gallbladder status in supine, left lateral decubitus, and sitting positions. Two examinations 
were performed: the first was done in a fasting condition (at least 4 hours) and a second 
scanning was conducted 30 minutes after the ingestion of a standard fatty meal (breakfast). 
Beside the detection of gallstones or sludge in the intrahepatic biliary tracts, pre- and 
postprandial gallbladder volume (fasting volume, residual volume, contraction index
15
) and 
septums or kinking of the gallbladder were evaluated. 
 
Statistical analyses 
Body mass index (BMI, kilogram/m
2
) was calculated from height and weight measurements. 
Computations of z scores for height, weight, and BMI were made using the National Center 
for Health Statistics standards.
21
 Data were tabulated using standard descriptive statistics. 
Two sample Student’s t-tests were performed to detect differences in fasting volume, residual 
volume and contraction index between this clinical sample and control females and females 




Part 3: Assessment and management guidelines 
A literature search of electronic databases and online libraries of guidelines was undertaken 
using keywords of Rett syndrome, developmental disability, intellectual disability, 
comorbidity, and gallbladder-related terms. The search was limited to full papers in English 
from 1986 to 2011. Statements relevant to the clinical assessment and management of 
gallbladder disease in RTT were extracted from the full text. 
Clinicians with experience with RTT from different countries in the disciplines of 
developmental paediatrics and child neurology, gastroenterology, paediatric surgery and 









Delphi study aiming to develop assessment and treatment recommendations for 
gastrointestinal issues in RTT including poor growth, gastroesophageal reflux, constipation, 
and abdominal bloating.
22
 Of the 20 medical clinicians participating in the larger study, 16 
(80.0%) participated in the section on gallbladder disease. 
Referenced statements extracted from the literature were accompanied by a 5-point 
Likert scale for agreement rating (strongly agree, agree, neither agree or disagree, disagree, 
strongly disagree) with space for comments. The statements and questions were listed in a 
Microsoft Word document format and an online version was also created as previously 
described.
22
 Consensus was attained when a minimum of 70% of responses were within one 
response category of the median response.
22
 Response to the first round of the Delphi process 
informed the second set of items until consensus was reached. A level of evidence was 
applied to each item for which there was consensus: level 1 representing evidence from 
systematic reviews and randomised controlled trials, level 2 case control or cohort studies, 
level 3 case reports or case series, and level 4 expert opinion.
23
 
 The statistical analyses were conducted using Stata version 12 (StataCorp 2012). 
 Ethical approval for Part 1 of the study was provided by the ethics committee of 
Princess Margaret Hospital in Western Australia (1909/EP). Part 2 was approved by the 
ethics committee of the Medical University Vienna. Part 3 was approved by the ethics 
committee of the University of Western Australia. 
 
RESULTS  
Part 1: Occurrence of gallbladder disease 
There were 270 individuals from ARSD and 749 from InterRett with a pathogenic MECP2 
mutation who were eligible for the study. The mean observation times were 16.2 years (SD 
8.6) and 10.5 years (SD 9.4) for the ARSD and InterRett cohort respectively. 
At the time of data analysis, ten individuals from ARSD and 14 from InterRett had 
been diagnosed with cholelithiasis and/or underwent cholecystectomy. The youngest age of 
cholecystectomy was 3 years in one of the Australian females, who also had a diagnosis of 
Down syndrome.
17
 The remainder of individuals in the ARSD cohort were 18, 20, 22, 22, 24, 
25, 29, 30, and 31 years old. A similar pattern was noted in the InterRett cohort, with four 
individuals younger than 18 years (4, 12, 15, 17), with the remaining (n=10) aged 18 to 47 
years. The incidence rate of occurrence of gallbladder disease was 2.3 (95% CI 1.1 to 4.2) 




respectively. This equates to approximately two new cases of gallbladder disorder if 100 
individuals with RTT are followed for 10 years. 
 
Part 2: Gallbladder function in a clinic sample 
The mean age of the 25 females was 16.4 (SD 10.7) years (range 3.4-47.8). A pathogenic 
mutation was identified in 17 out of 25, and no mutation or one with uncertain pathogenicity 
in 8 out of 25. Twenty were able to eat varied consistencies of food, three (12%) ate pureed 
food, and two were fed via a gastrostomy. Caregiver-reported gastrointestinal symptoms 
including recurrent unexplained vomiting in 3 out of 25 and suspected abdominal pain in 9 
out of 25. No history of gallstones or cholecystectomy was reported, although there was a 
family history in 9 out of 24. The females were usually underweight with a mean BMI z 
score of -2.8 (SD 3.6, range -13.8 to 1.6). Laboratory data from fasting blood tests revealed 
slightly elevated bile acids in 9 out of 25 patients and mild hypercholesteraemia in 8 out of 25 
patients. Glutamate dehydrogenase, complete blood cell count, electrolytes, liver and renal 
function tests, and also clotting tests were within normal ranges for age. 
The biliary tract was normal in all participants, although the gallbladder was septated in 
6 out of 25. There was gallbladder sludge in 1 out of 25 but no gallstones were found. The 
mean fasting volume was 7755 (SD 7898 mm
3
; n=16), and the mean residual volume 3624 
(SD 3609 mm
3
; n=16). The mean contractility index was 46.5 (SD 38.3%) similar to what 
has been reported for Down syndrome
15






Part 3: Assessment and management guidelines 
The recommendations of the expert panel of clinicians are shown in Table III. In summary, 
screaming and apparent abdominal pain were considered suggestive of gallbladder disease, 
often in association with fever and vomiting.
24,25
 After excluding gastrooesophageal reflux as 
the source of pain,
26
 the panel recommended diagnostic tests including ultrasound to examine 
for gallstones and a hepatobiliary iminodiacetic acid scan to examine the rate at which bile is 
ejected from the gallbladder.
25,27
 There was no consensus in favour of or against use of 
ursodeoxycholic acid to dissolve gallstones in RTT. In addition to appropriate analgesia, 
cholecystectomy was recommended for symptomatic biliary dyskinesia, cholelithiasis and in 
all symptomatic patients with calcified stones,
24,28,29
 but not for those with cholecystitis or 






Our analyses indicate that the prevalence of gallbladder disorder in RTT is approximately 2% 
in females who are followed for 10 years. This prevalence appears greater than in the general 
paediatric population but similar to that reported for individuals with Down syndrome. The 
gallbladder in females with RTT was small with poor contractility compared with healthy 
controls. Gallbladder disorders should be considered in the differential diagnosis when a 
female with RTT presents with abdominal pain and clinicians need to be aware of this 
possibility and its management. 
Established in 1993, the Australian Rett Syndrome Database ascertains cases from 
multiple sources, has collected longitudinal population data,
19
 and is thus an ideal research 
tool to estimate the epidemiology of clinical aspects of RTT. The incidence rate was 2.1 per 
1000 person-years in the ARSD cohort, equating to approximately two new cases of 
gallbladder disorder if 100 individuals are followed for 10 years. Analysis of the InterRett 
data found a similar incidence rate and, although not population-based, the sample size is 
large,
20
 providing opportunity to confirm the population-based findings. These parallel 
analyses found that, although gallbladder cholelithiasis and/or cholecystectomy are still rare 
in RTT, they do occur more commonly than would be expected in females of a similar age in 
the general population. 
Pain is the main symptom of gallbladder disease, usually occurring in intense and 
recurrent attacks, but it can become less severe and intermittent with time. If cholecystitis 
develops, there may also be symptoms of fever, jaundice, and vomiting.
26
 The 
communication deficit in RTT creates additional challenges for the assessment of abdominal 
pain, which can be further complicated by altered pain sensitivity, with decreased sensitivity 
to pain observed more frequently than increased sensitivity to pain, although increased 
sensitivity to pain may relate to internal rather than external sources of pain.
18
 Visceral pain 
possesses unique characteristics: both vagal and spinal afferents contribute to the sensory 
experience, and emotional and autonomic components are also strong.
30
 It is not surprising 
that pain relating to gallbladder disease can be extremely distressing to the female with RTT 
and also problematic to diagnose. In the presence of abdominal pain, a thorough clinical 
history and examination taking account of gastrooesophageal reflux and gallbladder disorder 
should be included in the differential diagnosis. There is no consensus for medical treatment 
of gallstones with ursodeoxycholic acid in keeping with the poor evidence base for its 






 Follow-up and clinical review of those with RTT who undergo cholecystectomy 
is necessary to develop the evidence-base for this painful comorbidity in RTT. 
Ingestion of inadequate quantities of food and fluids, low levels of mobility, 
infections, and medications can all contribute to inadequate gallbladder contraction and 
emptying, leading to bile stasis, sludge, cholecystitis and development of gallstones.
8,24
 
Repeated episodes of cholecystitis cause scarring of the gallbladder and further loss of 
gallbladder motility. The gastrointestinal dysmotility frequently found in RTT may likely be 
associated with gallbladder disease. We found that the mean contractility index for our 
clinical sample was 46.5% suggesting gallbladder hypomotility, although there was no 
evidence of gallstones in any of the 25 individuals. This index was at a similar level to that 
reported (41.2%) in a small sample of Down syndrome patients (n=9) and markedly lower 
than reported (75.0%) for healthy control individuals (n=10).
15
 In Down syndrome, 
gallbladder abnormalities have been found in 9.1% (6.9% cholelithiasis and 2.1% biliary 
sludge),
31




 Similar to Down syndrome, the 
immature enteric nervous system in females with RTT might have contributed to the 
dysfunction in the gastrointestinal tract.
32,33
 
The exact pathophysiological cause of the problem has yet to be found,
33
 although a 
role for aberrant MECP2 gene function in the pathogenesis of gallbladder symptoms is 
possible. Abnormal cholesterol metabolism has recently been identified in male Mecp2-null 
and female Mecp2 mutant mice. In comparison with control individuals, these mice had 
higher lipid concentrations thought to arise from systemic dyslipidaemia, which is also a risk 
factor for gallstones.
34
 Although the underlying mechanisms are unknown, the mouse data 
support the idea that genes involved in lipid homeostasis are regulated by chromatin-
remodelling complexes that involve the MECP2 gene.
35
 Biological processes associated with 
gallbladder function such as cholesterol metabolism, biliary lipid secretion, lipid transport, 
and gallbladder contractility are regulated by a variety of transcription factors and nuclear 
receptors including the liver X receptor (LXR), the farnesoid X receptor (FXR) and the 
oestrogen receptor alpha (ESR1).
36
 The MeCP2 protein is involved in the epigenetic 
regulation of the oestrogen receptor alpha ESR1,
37,38
 and this receptor has been implicated in 
abnormal cholesterol metabolism leading to gallstone disease.
36
 It is thus possible that 
aberrant MECP2 gene function contributes to gallbladder disease, through multiple gene 
regulatory pathways. 
Epidemiological estimates were based on population-based and longitudinal data, and 




therefore more likely to be an underestimate. Our clinical sample was small but our findings 
were still statistically significant suggesting that Type II error was unlikely. For our 
consensus study, the level of evidence was low and of necessity, our expert panel drew 
heavily on their clinical expertise. 
We have conducted the first population-based estimate of the epidemiology of 
gallbladder disorder in RTT using the Australian Rett Syndrome Database, confirming the 
findings using the large sample size available in the InterRett. Our ultrasonographic data 
identified smaller gallbladder volumes and decreased contractility in RTT compared with 
healthy control individuals and similar to those with Down syndrome. Gallbladder disease 
appears to occur more commonly in RTT than in the general population and therefore is 
considered in the differential diagnosis of abdominal pain when it presents in this disorder. 
The consensus of 16 expert clinicians on the assessment and management of gallbladder 
disease in RTT represents a platform for the development of more consistent clinical care and 
research initiatives on this infrequent entity in a rare disorder. 
 
ACKNOWLEDGEMENTS 
We are indebted to the families for their continued support throughout the study and we thank 
the Austrian Rett Syndrome Society for their administrative assistance. The authors would 
also like to acknowledge the International Rett Syndrome Foundation (IRSF previously 
IRSA) for their ongoing support of the InterRett project and their continued encouragement 
of this international collaboration. The Australian Rett Syndrome Study was funded by the 
National Institutes of Health (5R01HD043100–05) and also by the National Health and 
Medical Research Council (NHMRC) project grant 303189 for certain clinical aspects. Helen 
Leonard was previously funded by a NHMRC programme grant 353514. Her current funding 
is from an NHMRC Senior Research Fellowship 572568. The funders have not been involved 
in decisions pertaining to study design, data collection, data analysis, manuscript preparation 
nor publication decisions. We also acknowledge the expert panel in the Delphi technique. 
(Names of the panel members can be found in Appendix S1, online supporting information)   
The authors have reported no conflicts of interest or financial associations. 
 
REFERENCES 
1. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-




2. Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and 
nomenclature. Ann Neurol 2010; 68: 944–50. 
3. Motil KJ, Schultz RJ, Browning K, Trautwein L, Glaze DG. Oropharyngeal dysfunction 
and gastroesophageal dysmotility are present in girls and women with Rett syndrome. J 
Pediatr Gastroenterol Nutr 1999; 29: 31–7. 
4. Oddy WH, Webb KG, Baikie G, et al. Feeding experiences and growth status in a Rett 
syndrome population. J Pediatr Gastroenterol Nutr 2007; 45: 582–90. 
5. Schwartzman F, Vitolo MR, Schwartzman JS, Morais MB. Eating practices, nutritional 
status and constipation in patients with Rett syndrome. Arq Gastroenterol 2008; 45: 284–9. 
6. Motil KJ, Caeg E, Barrish JO, et al. Gastrointestinal and nutritional problems occur 
frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol 
Nutr 2012; 55: 292–8. 
7. Debray D, Franchi-Abella S, Irtan S, Girard M. [Cholelithiasis in infants, children and 
adolescents]. Presse Med 2012; 41: 466–73. 
8. Wesdorp I, Bosman D, de Graaff A, et al. Clinical presentations and predisposing factors 
of cholelithiasis and sludge in children. J Pediatr Gastroenterol Nutr 2000; 31: 411–7. 
9. Palasciano G, Portincasa P, Vinciguerra V, et al. Gallstone prevalence and gallbladder 
volume in children and adolescents: an epidemiological ultrasonographic survey and 
relationship to body mass index. Am J Gastroenterol 1989; 84: 1378–82. 
10. Koebnick C, Smith N, Black MH, et al. Pediatric obesity and gallstone disease. J Pediatr 
Gastroenterol Nutr 2012; 55: 328–33. 
11. Kratzer W, Walcher T, Arnold F, et al. Gallstone prevalence and risk factors for gallstone 
disease in an urban population of children and adolescents. Z Gastroenterol 2010; 48: 683–7. 
12. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of gallstone disease in a general 
population of Okinawa, Japan. Am J Epidemiol 1988; 128: 598–605. 
13. Toscano E, Trivellini V, Andria G. Cholelithiasis in Down's syndrome. Arch Dis Child 
2001; 85: 242–3. 
14. Tyler CV, Jr., Zyzanski SJ, Runser L. Increased risk of symptomatic gallbladder disease 
in adults with Down syndrome. Am J Med Genet A 2004; 130A: 351–3. 
15. Tasdemir HA, Cetinkaya MC, Polat C, et al. Gallbladder motility in children with Down 
syndrome. J Pediatr Gastroenterol Nutr 2004; 39: 187–91. 
16. Budden SS, Dorsey HC, Steiner RD. Clinical profile of a male with Rett syndrome. Brain 




17. Leonard H, Weaving L, Eastaugh P, et al. Trisomy 21 and Rett syndrome: a double 
burden. J Paediatr Child Health 2004; 40: 406–9. 
18. Downs J, Geranton SM, Bebbington A, et al. Linking MECP2 and pain sensitivity: the 
example of Rett syndrome. Am J Med Genet A 2010; 152A: 1197–205. 
19. Laurvick CL, de Klerk N, Bower C, et al. Rett syndrome in Australia: a review of the 
epidemiology. J Pediatr 2006; 148: 347–52. 
20. Louise S, Fyfe S, Bebbington A, et al. InterRett, a model for international data collection 
in a rare genetic disorder. Res Autism Spectrum Dis 2009; 3: 639–59. 
21. National Center for Health Statistics. (2001) National Health and Nutrition Examination 
Survey. 
22. Leonard H, Ravikumara M, Baikie G, et al. Assessment and management of nutrition and 
growth in Rett syndrome. J Pediatr Gastroenterol Nutr 2013; 57(4): 451-60 
23. SIGN. (2011) SIGN 50: A guideline developer's handbook. Edinburgh (UK). 
24. Holcomb GW, Jr., Holcomb GW, 3rd. Cholelithiasis in infants, children, and adolescents. 
Pediatr Rev 1990; 11: 268–74. 
25. Greenberg M, Kangarloo H, Cochran ST, Sample WF. The ultrasonographic diagnosis of 
cholecystitis and cholelithiasis in children. Radiology 1980; 137: 745–9. 
26. Lugo-Vicente HL. Trends in management of gallbladder disorders in children. Pediatr 
Surg Int 1997; 12: 348–52. 
27. Vegunta RK, Raso M, Pollock J, et al. Biliary dyskinesia: the most common indication 
for cholecystectomy in children. Surgery 2005; 138: 726–31; discussion 31–3. 
28. Al-Homaidhi HS, Sukerek H, Klein M, Tolia V. Biliary dyskinesia in children. Pediatr 
Surg Int 2002; 18: 357–60. 
29. Svensson J, Makin E. Gallstone disease in children. Semin Pediatr Surg 2012; 21: 255–
65. 
30. Bielefeldt K, Christianson JA, Davis BM. Basic and clinical aspects of visceral sensation: 
transmission in the CNS. Neurogastroenterol Motil 2005; 17: 488–99. 
31. Boechat MC, Silva KS, Llerena JC, Jr., Boechat PR. Cholelithiasis and biliary sludge in 
Downs syndrome patients. Sao Paulo Med J 2007; 125: 329–32. 
32. Sullivan PB. Gastrointestinal disorders in children with neurodevelopmental disabilities. 
Dev Disabil Res Rev 2008; 14: 128–36. 
33. Martinelli M, Staiano A. Motility problems in the intellectually challenged child, 




34. Di Ciaula A, Wang DQH, Bonfrate L, Portincasa P. Current views on genetics and 
epigenetics of cholesterol gallstone disease. Cholesterol 2013; 2013: 298421. 
35. Buchovecky CM, Turley SD, Brown HM, et al. A suppressor screen in Mecp2 mutant 
mice implicates cholesterol metabolism in Rett syndrome. Nat Genet 2013; 45: 1013-20. 
36. Vazquez MC, Rigotti A, Zanlungo S. Molecular Mechanisms Underlying the Link 
between Nuclear Receptor Function and Cholesterol Gallstone Formation. J Lipids 2012; 
2012: 547643. 
37. Sharma D, Blum J, Yang X, et al. Release of methyl CpG binding proteins and histone 
deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-
negative human breast cancer cells. Mol Endocrinol 2005; 19: 1740–51. 
38. Westberry JM, Trout AL, Wilson ME. Epigenetic regulation of estrogen receptor alpha 
gene expression in the mouse cortex during early postnatal development. Endocrinology 
2010; 151: 731–40. 
39. Everhart JE, Khare M, Hill M, Maure KR. Prevalence and ethnic differences in 
gallbladder disease in the United States. Gastroenterology 1999; 117: 632–9. 
40. Bailey PV, Connors RH, Tracy TF, Jr., et al. Changing spectrum of cholelithiasis and 




Table I: Literature review of epidemiology of gallbladder disorders in children. 
Reference Inclusion criteria Study design and population Point prevalence of gallbladder disease, % (95% CI) 




from medical records 
within 2 years of 
enrolment 
Population-based, members of the Kaiser 
Permanente Southern California health plan 
Cross-sectional 
510 816 children 
Mean age 15.1±2.9 years (range 10–19 years) 
 766 patients with gallstones identified (766/510 816, 0.15%) 
 Point prevalence: 
Total 0.15 (0.14 to 0.16) 
Male 0.06 (0.05 to 0.07) 
Female 0.24 (0.22 to 0.26) 




Population-based, random sampling in an 
urban area of a small town in Germany 
Cross-sectional 
307 children 
Mean age 15.1±2 years (range 12-18 years) 
 %, showed gallstones (1 female and 2 male adolescents) 
 Point prevalence: 
Total 0.98 (- to 2.08) 
Male 1.33 (- to 3.17) 
Female 0.64 (- to 1.88) 




Clinical study of patients referred for 
problems unrelated to gallstones 
Cross-sectional 
139 children with Down syndrome 
Age: median 36mo, range 1mo-19y 
577 healthy controls 
Age: median 40mo, range 1mo to 19y 
 Point prevalence: 
Total 1.00 (0.26 to 1.73) 
DS 4.76 (1.04 to 8.48) 
Control 0.17%(- to 0.51) 
(No female/male data in those without gallbladder disease hence no 
prevalence by sex) 
 4.7% of those with DS had cholelithiasis, 4 females under 21 months 
and 2 males aged 6 years (out of 126 patients). One 7-year-old 
female in the control group was diagnosed with cholelithiasis (0.2%) 
Wesdorp et al. 
20008 
Cholelithiasis Clinical study 
4200 children 
Age: median ~11y, range 0–18y 
 Idiopathic gallstones were found in 19 (23%) patients. Gallstones in 
association with haemolytic disease in 32 (39%) 
 Point prevalence (n=4200): 









Non-random sampling from town of Bari, 
Italy (population 400 000) 
Cross sectional 
1492 children 
Age: mean 12±4y, range 6–19y 
 Overall prevalence of gallstone disease = 0.13%. 
 Point prevalence: 
Total 0.13 (- to 0.32) 
Male 0 
Female 0.27 (- to 0.64) 
Nomura et al. 
198812 
Presence of gallstones 
on ultrasound 
Population-based study, >83% of population 







 0% in under 19 years of age  
20–29 year olds ~3.0% 
30 -39 year olds ~3.5% 
 Point prevalence in the 20–39y age group: 
Total 2.07 (0.86 to 3.28) 
Male 1.38 (0.04 to 2.73) 
Female 2.89 (0.78 to 5.00) 




Population-based as part of the NHANES III 
study 
Cross-sectional 
14 238 adults 
3420 were 20–29y 
3231 were 30–39y 
 Point prevalence in 20–29y: 
Total 101/3420 = 2.95 (2.39 to 3.52) 
Male 21/1602 = 1.31 (0.75 to 1.87) 
Female 80/1818 = 4.40 (3.46 to 5.34) 
 Point prevalence in 30–39y: 
Total 110/3231 = 3.40 (2.78 to 4.03) 
Male 16/1426 = 1.12 (0.58 to 1.67) 
Female 94/1805 = 5.21 (3.46 to 5.34) 






Clinical case control study 
Down syndrome, n = 28 
Age: mean 43.0±10.0y 
Healthy controls, n = 112 
 Prevalence for total sample: 
Total 8.57 (3.93 to 13.21) 
Male 3.08 (- to 7.28) 




Age: mean 43.1±10.0y  Prevalence for those with Down syndrome: 
25.00 (8.96 to 41.04) 
Male 7.69 (- to 22.18) 
Female 40.00 (15.21 to 64.79) 
 Prevalence for control children 
Control 4.46 (0.64 to 8.29) 
Male 1.92 (- to 5.66) 
Female 6.67 (0.35 to 12.98) 
  
Table II: Gallbladder fasting volume, resting volume and contraction indices for females 
with Rett syndrome, Down syndrome
a













Mean difference: Rett and 
Down syndrome 
Mean difference: Rett 
syndrome and healthy 




















































(-20.9 to 25.6) 
0.839 
-32.7 
(-54.6 to -10.8) 
0.005 
a Group data describing individuals with Down syndrome and healthy control individuals derived from 
Tasdemir (2004).15 





Table III: Clinical assessment and treatment of gallbladder problems in Rett syndrome. 









1. Screaming or apparent abdominal pain is suggestive of 
gallbladder disease24 
4 Agree 15/16 
(93.8) 
2. The triad of apparent pain, vomiting and fever is the usual 
mode of presentation of cholecystitis25  
3 Agree 16/16 
(100) 
3. Exclude GERD as a cause of pain26 3 Agree 15/16 
(93.8) 
4. An ultrasound scan can be used to identify the presence of 
gallstones25 
3 Agree 15/16 
(93.8) 
5. Oral cholecystogram or a CCK or HIDA scan can be used to 
confirm biliary dyskinesia25,27,29 
3, 3, 3 Agree 13/13 
(100) 
Treatment 
1. Ursodeoxycholic acid may be considered in an asymptomatic 
patient with gallstone(s) 








3. Cholecystectomy can be considered in cases of cholecystitis 
after antibiotic treatment 
 Agree 14/15 
(93.3) 
4. Cholecystectomy is advised for all non-symptomatic patients 
with sludge or non-calcified stones that have not resolved in 2 to 
3 months40 




4. The treatment of symptomatic biliary dyskinesia is 
cholecystectomy28 
3 Agree 11/13 
(84.6) 
5. The treatment of cholelithiasis is cholecystectomy24 4 Agree 13/14 
(92.9) 
GERD, Gastro-esophageal reflux disease; CCK, Cholecystokinin;HIDA, hepatobiliary iminodiacetic acid. 
a Scottish Intercollegiate Guidelines Network. 
b numerator is the number of responses with median response or one category either side and denominator is the 
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